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Mesenchymal stem cells and T 
cells in the formation of Tertiary 
Lymphoid Structures in Lupus 
Nephritis
S. Esmaeil Dorraji  1, Aud-Malin K. Hovd1, Premasany Kanapathippillai1, Gunnstein Bakland2,3, 
Gro Østli Eilertsen2,3, Stine L. Figenschau  1 & Kristin A. Fenton  1
Tertiary lymphoid structures (TLS) develop in the kidneys of lupus-prone mice and systemic lupus 
erythematosus (SLE) patients with lupus nephritis (LN). Here we investigated the presence of 
mesenchymal stem cells (MSCs) in the development of TLS in murine LN, as well as the role of human 
MSCs as lymphoid tissue organizer (LTo) cells on the activation of CD4+ T cells from three groups of 
donors including Healthy, SLE and LN patients. Mesenchymal stem like cells were detected within the 
pelvic wall and TLS in kidneys of lupus-prone mice. An increase in LTβ, CXCL13, CCL19, VCAM1 and 
ICAM1 gene expressions were detected during the development of murine LN. Human MSCs stimulated 
with the pro-inflammatory cytokines TNF-α and IL-1β significantly increased the expression of CCL19, 
VCAM1, ICAM1, TNF-α, and IL-1β. Stimulated MSCs induced proliferation of CD4+ T cells, but an 
inhibitory effect was observed when in co-culture with non-stimulated MSCs. A contact dependent 
increase in Th2 and Th17 subsets were observed for T cells from the Healthy group after co-culture with 
stimulated MSCs. Our data suggest that tissue-specific or/and migratory MSCs could have pivotal roles 
as LTo cells in accelerating early inflammatory processes and initiating the formation of kidney specific 
TLS in chronic inflammatory conditions.
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by systemically deposition of 
immune complexes (ICs), inflammation and subsequent infiltration of immune cells1,2. In lupus nephritis (LN) 
the deposition of ICs within the glomeruli and tubule interstitial area activate intrinsic kidney and immune cells 
to produce chemokines attracting more effector cells3. Infiltration of immune cells and formation of aggregates in 
LN are associated with the development of tertiary lymphoid structures (TLS) in both human and murine LN4,5.
The formation of TLS is a dynamic process starting with sparse lymphocytic infiltrates that evolve into aggre-
gates and eventually organize into distinct T cell areas and B-cell follicles with germinal centers6,7. During second-
ary lymphoid organ (SLO) development specialized hematopoietic lymphoid tissue inducer (LTi) cells interact 
with stromal lymphoid tissue organizer (LTo) cells with a mesenchymal origin, in a process involving LTα1β2 sig-
naling to LTβR, which cause LTo cells to express several adhesion molecules (ICAM1, VCAM1, and MAdCAM1) 
and homeostatic chemokines (CCL19 and CXCL13)8,9. The nature and involvement of LTi and LTo cells in the 
induction of TLS is controversial8. In TLS formation, it is believed that immune cells may take the role of LTi 
cells10. Especially the T helper (Th) 17 subset of CD4+ T cells play a central role in the induction of TLS11, and 
various activated resident stromal cells have been shown to be important origin of LTo cells12,13. In addition to the 
known cytokines and chemokines involved in SLO formation, proinflammatory cytokines such as TNF-α and 
IL-1β have been implicated in the induction and development of TLS14,15. High expression of TNF-α in tissue 
can induce TLS formation in the absence of LTi cells, indicating a role for TNF-α producing myeloid cells14. The 
expression of IL-1β is important in Th17 activation and thus indirectly involved in TLS formation16.
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Mesenchymal stem cell (MSCs) are adult multipotent progenitor cells, which exist in almost all tissues, and are 
assumed immunomodulators17–20. This function makes them the most prominent therapeutic candidate for auto-
immune and inflammatory diseases, as they can inhibit dendritic and T cell proliferation and maturation21. On 
the other hand, based on new evidence, MSCs may have immunostimulatory potentials in specific circumstances, 
such as low concentration of pro-inflammatory cytokines, and low number of MSCs compared to immune cells 
in inflamed tissue, which is highly controversial22,23. Hitherto, few studies have suggested that MSCs may have 
immunostimulatory potential. In the review by Ma et al. it is suggested that inadequate inflammatory cytokines at 
chronic inflammatory sites could induce MSCs to produce chemokines and other attracting factors in absence of 
sufficient immune inhibitory factors18. Since MSCs subsist in almost all tissues, their immunostimulatory poten-
tials could play a fundamental role in initiating an inflammatory process in autoimmune diseases. We hypothesize 
that MSCs play a crucial role as LTo cells, which trigger inflammatory signaling cascade in the kidney that leads 
to recruitment of immune cells and subsequently TLS formation. We investigated the effect of MSCs on T cell 
from healthy donors and SLE patients with or without LN. Our results indicate that MSCs in a pro-inflammatory 
milieu may stimulate CD4+ T cell proliferation and differentiation into Th2 and Th17 effector cells.
Results
Mesenchymal stromal-like cells are detected within the kidneys of young lupus-prone mice and 
within the developed TLS. Since MSCs play a pivotal role in SLOs function, organization, and tissue homeosta-
sis and SLOs share similarity with TLS in function and structure24,25, we investigated the localization of mesenchymal 
stem-like cells (MSLCs) in kidneys of lupus-prone mice. In young Ab− mice (6 wo), Nestin+Sca1+PDGFRα+CD45− 
MSLCs were mostly located in the pelvic wall, and CD45+ tissue-residential immune cells were located at the 
edge of the pelvic wall surrounded by MSLCs (Fig. 1a). In older Ab+ (30 wo)and proteinuric (27 wo) mice the 
Nestin+Sca1+PDGFRα+CD45− MSLCs were detected in the pelvic wall around and within the TLS and adjacent to 
CD45+ immune cells with a lower ratio (Fig. 1b,c, respectively). The signal intensity graphs indicate that the areas 
positive for PDGFRα were negative for CD45 and contrariwise (Supplementary Fig. S1). We also observed GCs with 
supporting FDC network and distinct T cell zones in Ab+ and proteinuric lupus-prone mice (Fig. 2)
The renal pelvis areas of these mice were also evaluated for the presence of T and B cells (Fig. 3). Residential T 
cells were found in the pelvis wall of young Ab- mice. However, B cells were not detected in these areas (Fig. 3a). 
In Ab+ + mice the majority of the immune cells within TLS were T cells (Fig. 3b), whereas, in proteinuric mice 
with extensive TLS formation, there were more B cells. The majority of cells were still T cells, but at a lower ratio 
compared to Ab+ mice (Fig. 3c). The expression of cytokines and chemokines essential for TLS development in 
kidneys of NZB/W was detected at different ages. The mRNA expression of Ltb, Vcam1, Icam1, Ccl19, and Cxcl13 
were significantly increased during disease progression in the kidneys of 18 weeks old (wo) and older anti-dsDNA 
Ab+ NZB/W mice (Fig. 4a,c–f, respectively). The expression of LTβR seemed to be unchanged although a sig-
nificant increase was observed in the proteinuric mice of age 23–39 wo (Fig. 4b). To measure the expression of 
these genes within the TLS compared to the kidney expression, RNA were isolated from TLS and kidney tissue 
dissected from 25–36 wo proteinuric NZB/W mice and analyzed by qPCR (Fig. 4g–l). The results revealed an 
increased expression of Ltb, Ccl19 and Cxcl13 in TLS compared to the kidney (Fig. 4g,k and l). The expression of 
Ltbr was increased in kidneys compared to TLS (Fig. 4h).
Human MSCs express TNF-α, IL-1β, CCL19 and ICAM1 upon stimulation with inflammatory 
cytokines. We evaluated the MSCs response to an inflammatory and anti-inflammatory environment by 
stimulating the cells with different cytokines (Fig. 5 and Supplementary Tables S1 and S2). MSCs stimulated with 
TNF-α or IL-1β expressed higher levels of CCL19 and ICAM1 compared to unstimulated controls (Fig. 5a,b). 
TNF-α, IL-6 or INF-α induced IL-1β expression (Fig. 5a,c,d), whereas IL-1β or IFN-γ resulted in higher levels 
of VCAM1 (Fig. 5b,e), and IL-1β increased the expression of TNF-α in MSCs (Fig. 5b). The anti-inflammatory 
cytokine IL-10 did not induce any significant increase or decrease in the gene expression of the analyzed genes 
(Supplementary Table S2). Unstimulated MSCs (nsMSCs) expressed high basal levels of VCAM1, ICAM1, LTβR, 
CXCL12, and lower levels of IL-1β, PDPN, and IL-7 (Supplementary Tables S1 and S2).
The inflammatory property of MSCs was further assessed by dual IL-1β and TNF-α stimulation. Stimulated 
MSCs (sMSCs) expressed higher mRNA levels of CCL19, IL-1β, TNF-α, ICAM1, and VCAM1 compared to the 
controls and to nsMSCs at zero hour (Fig. 5f–j). At the protein level, the expression of VCAM1, ICAM1, IL-1β, 
and TNFα was detected in sMSCs (Fig. 5k). Other candidates for LTo cells are endothelial and epithelial cells. 
To investigate if such cells responded similar to cytokines as the MSCs, endothelial (HUV-EC_C) and epithelial 
cells (HMLE) were stimulated with IL-1β and TNF-α. These cells showed similar expression pattern as sMSCs 
(Supplementary Fig. S2A–G). However, no expression of CCL19 and CXCL13 were observed.
CD4+ T cells proliferate in co-culture with MSCs. In the induction and expansion of TLS activated organ-
izer cells will recruit naïve T cells. We therefor investigated the proliferative response of CD4+ T cells isolated from 
peripheral blood of healthy donors, SLE, and LN patients (Supplementary Table S3) by co-culturing the cells with 
sMSCs or nsMSCs. No clear increase in T cell proliferations at 1:1 co-culture were observed after ten days (Fig. 6a–c). 
However, the presence of sMCSs and nsMSCs in co-culture at 1:100 ratio initiated a proliferative response of CD4+ T 
cells, compared to T cells cultured alone (Fig. 6d–f). In addition, co-culture with sMSCs induced a significantly higher 
proliferation of T cells in the Healthy and SLE group compared to nsMCSs, indicating the importance of stimulation 
of MSCs upon inducing T cell proliferation (Fig. 6d,e). However, this was not observed for T cells from the LN group 
(Fig. 6f) and neither for healthy donors in a Transwell system (Fig. 6g,h), suggesting a contact dependent inhibition of T 
cell proliferation by nsMSC for the Healthy and SLE group (Fig. 6d,e). Interestingly, there was no significant difference 
between CD4+ T cells co-cultured with non-stimulated HUV-EC-C (nsHUVs) and stimulated HUVs (sHUVs) on day 
ten at 1:1 or 1:100 ratio, indicating no contact dependent inhibition of T cell proliferation by HUVs (Fig. 6i,j).
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Healthy CD4+ T cells differentiate in co-culture with stimulated MSCs in direct contact. To 
evaluate the immune-regulatory potential of MSCs on CD4+ T cell differentiation into the T helper cell subsets, 
sMSCs and nsMSCs were co-cultured with T cells from donors (Supplementary Table S3, Supplementary Fig. S3). 
CD4+ T cells isolated from the Healthy group co-cultured with sMSCs at 1:100 ratio had increased Th2 and Th17 
subsets compared to day zero (Fig. 7b,c). There were no difference in the Th1, Th9, Th1/17 and Th22 between the 
setups and groups (Fig. 7a,d,e and f). Using the Transwell system we observed no difference between the setups 
within the groups (Supplementary Fig. S4), which indicates a contact dependent differentiation of the Th2 and 
Th17 cells observed in Fig. 7b,c. No differences in the Th subsets were observed in T cells isolated from SLE and 
LN when co-cultured with nsMSCs and sMSCs (Fig. 7). The different Th subsets and the % of live CD4+ T cell 
populations measured at day 0 are listed in Supplementary Fig. S3.
MSCs co-cultured with T cells express CXCL13. We further examined the effect of co-culturing CD4+ T 
cells from the Healthy and LN group with MSCs on the expression of cytokines, chemokines and adhesion molecules. 
Figure 1. The presence of MSLCs can be detected within the pelvis wall and TLS of lupus-prone mice. MSLCs 
were detected by using antibodies against Nestin, Sca1, and PDGFRα and the cells were negative selected using 
antibodies against CD45. Kidney section from (a) anti-dsDNA Ab- (n = 3), (b) anti-dsDNA Ab+ (n = 3), and 
(c) proteinuric (n = 3) mice were analyzed by IHC. Scale Bar 20 μm. Magnification (a–c) 20X with digital zoom 
for magnified panels. (A: artery, Ab: anti-dsDNA antibody, G: Glomeruli, H: Hilum, PW: pelvic wall, T: tubule, 
US: urinary space, V: vein).
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sMSCs expressed significantly higher mRNA levels of LTβ, CCR7, IDO, HLA-DRA, IL-6 and IL-23 compared to nsM-
SCs on day zero (Fig. 8a). CD4+ T cells from the Healthy group induced expression of CXCL13, IDO, IL-21, and IL-23 
in sMSCs compared to nsMSCs cultured alone (Fig. 8b). However, in sMSCs co-cultured with T cells from the LN 
group (n = 3, patients 8, 9 and 10, Supplementary Table S3) no expression of CCL19, CXCL13, IDO, HLA-DRA, IL-21, 
and IL-23 were detected (Fig. 8c). This may indicate that the T cells from the LN group inhibit the expression of these 
genes. sMSCs co-cultured with CD4+ T cells from both groups expressed significantly higher levels of IL-1β, ICAM1, 
CCR7, and IL-6 compared to nsMSCs cultured alone (Fig. 8b,c). sMSCs and nsMSCs in co-culture with CD4+ T 
cells from LN group expressed higher levels of ICAM1, CCR7, and IL-6 indicating an activation of nsMSCs by the 
T cells (Fig. 8c). Interestingly, the expression pattern observed in nsHUVs and sHUVs after co-culture with CD4+ 
Figure 2. TLS contain germinal centers (GCs) with FDC network and B cells. Kidney sections from (a) anti-
dsDNA Ab+ mice (n = 10), (c) proteinuric (n = 10) mice, and (d) BALB/c mice (n = 10) were analyzed for the 
presence of B cells, T cells, and FDCs using antibodies against B220, CD3, and CD21 respectively, and DAPI 
to visualize the nucleus. TLS comprising (a,b) GCs with FDCs supporting networks and distinct T cell zone. 
Magnification (a–c) 20X. Scale Bar 20 μm.
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T cells isolated from peripheral blood of Healthy donors (n = 3), were similar as observed for nsMSCs and sMSCs 
(Supplementary Fig. S2).
Discussion
In an autoimmune scenery, the constant exposure of autoantigens will lead to the persisting activation of immune 
cells and subsequent development of TLS26. These processes increase the inflammatory cascade by providing 
local activation of immune cells and production of autoantibodies. TLS formation within tissues undergoing 
chronic inflammation requires cross talk between stromal cells as LTo cells and resident or recruited immune 
cells as LTi cells7,26,27. Persistent exposure to ectopic expression of proinflammatory cytokines causes fundamental 
changes in the stromal cells and lead to the expression of homeostatic chemokines and adhesion molecules, which 
result in recruiting, organizing and aberrant accumulation of immune cells5,13,27–34. However, it is still unclear 
whether MSCs can act as LTo cells in development of kidney-specific TLS, but our results suggest that resident 
tissue-specific MSCs could potentially reprogram as lymphoid like stromal cell in inflammatory milieu and act 
as LTo cells through interaction with T cells as LTi cells induce TLS formation and start the early inflammatory 
cascade. More important, the MSCs produced chemokines attracting naïve T cells, and unstimulated T cells pro-
liferated and differentiated when co-cultured with sMSCs.
We have previously demonstrated that IL-1β overexpression in lupus-prone mice is detectable at an early 
stage of disease35,36, and it has been shown that activation of the TNF-RI-signaling pathway is sufficient to induce 
upregulation of adhesion molecules and homeostatic chemokines, and TLS formation13,14,31,37. Peduto et al. were 
the first to demonstrate that stromal cells undergo changes at the site of inflammation38. They suggested that 
tissue-specific stromal cells, under inflammatory conditions, reprogram as “lymphoid” stromal cells. This gave 
them the competence to express homeostatic chemokines required for immune cells recruitment and mainte-
nance as has been observed in lymphoid organs38,39(1,2). These gp38+ “lymphoid” stromal cells could be gener-
ated from residential fibroblasts or mesenchymal precursors in inflamed tissue38(1). It has been shown that LTo 
cells in the lymph node express the mesenchymal lineage markers PDGFRα and PDGFRβ, and kidney-specific 
mesenchymal cells are PDGFRα posetive40–42. Koning et al. reported that the majority of lymph node stromal cell 
subsets are Nestin+ MSCs lineage. Nestin+ bone marrow MSCs could give rise to CD31−gp38+ mesenchymal 
and CD31+gp38+ endothelial LTo cells, which both play a crucial role in lymph node development43. This is in 
agreement with our results as we detected Nestin+Sca1+PDGFRα+CD45− MSCs and T cells in the pelvis wall 
Figure 3. T and B cell are accumulating within the pelvic wall during the formation of TLS. Kidney sections 
from (a) young anti-dsDNA Ab- mice (n = 24), (b) anti-dsDNA Ab+ (n = 27), and (c) proteinuric (n = 27) mice 
were analyzed for the presence of T and B cells using antibodies against CD3 and B220, respectively. Total RNA 
was isolated from NZB/W mice at different ages. (A: artery, Ab: anti-dsDNA antibody, G: Glomeruli, H: Hilum, 
PW: pelvic wall, T: tubule, US: urinary space, V: vein).
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Figure 4. Cytokines and chemokines attracting T and B cells are upregulated in kidneys during development 
of TLS and nephritis. The total kidney gene expression of (a) LTβ (n = 24, 27 and 26), (b) LTβR (n = 24, 24 and 
26), (c) VCAM1 (n = 35, 28 and 14), (d) ICAM1 (n = 23, 11 and 6), (e) CCL19 (n = 18, 19 and 26) (f) CXCL13 
(n = 24, 28 and 27) were analyzed by qPCR. mRNA expressions are shown as FC mean ± SEM compared 
to young 7 wo mice. Kruskal-Wallis test with Dunn’s Multiple Comparison Test. *P < 0.05; **P < 0.01; 
****P < 0.0001. Gene expression in isolated TLS and kidney tissue from proteinuric mice was normalized 
against average ΔCT of all kidney tissue samples (g–l). The gene expression in TLS and kidney tissue was also 
normalized to young 7 wo mice (second panel in g–l).
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Figure 5. Augmentation of proinflammatory cytokines and adhesion proteins in MSCs upon stimulation with 
TNF-α and IL-1β. MSCs (n = 3) were stimulated for 24 h with different concentrations of (a) TNF-α (b) IL-1β 
(c) IL-6 (d) IFN-α and (e) INF-γ. mRNA expressions are shown as FC mean ± SEM compared to control (Ctr). 
MSCs (n = 3) were stimulated with a combination of IL-1β and TNF-α (8 ng/ml) and mRNA expression of (f) 
CCL19, (g) IL-1β, (h) TNF-α, (i) ICAM1, and (j) VCAM1 were measured after 1–72 h. Results are shown as 
FC mean ± SEM compared to Ctr at the same time point. (k) The protein expression of MSCs were analyzed by 
Western blotting using antibodies against VCAM1, ICAM1, IL-1β, TNF-α and Actin. The quantitative ratio to 
actin was measured (k). (a–e) Two-way ANOVA with Post-hoc analysis Dunnett’s multiple comparisons test 
within a group toward Ctr (*). (f–j) Two-way ANOVA with Post-hoc analysis Sidak’s (compare between the 
groups Ctr and stimulated at given time point, marked with *) and Dunnett’s (compare within a group toward 
zero hour time point, marked with #) multiple comparisons tests. */#P < 0.05; **/##P < 0.01; ***/###P < 0.001; 
****/####P < 0.0001.
www.nature.com/scientificreports/
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of autoantibody negative lupus-prone mice. In addition, We demonstrated that kidney-specific TLS comprise 
T cell areas and GC like structures with supporting FDCs network in autoantibody positive and proteinuric 
mice. If MSCs are originating from kidneys itself or if they are migrating from the bone marrow are not know. 
Consequently, MSCs can differentiate into other stromal cells, through interaction with CD4+ T cells and acti-
vation through TNF-receptor signaling, provided by early inflammatory stimuli or B cells28,37,44. Thus, aberrant 
immune cell accumulation and MSCs differentiation leads to enlargement of lymphatic networks and vessels, and 
the expansion of TLS45.
Several studies have shown that MSCs possess two distinct regulatory potential depending on the MSCs ratio 
that could inhibit or promote T cell proliferation32–34. Blanc et al. showed that high number of MSCs resulted 
in suppression of T cell activity, whereas an enhancement of proliferation was observed at the low number of 
Figure 6. CD4+ T cells proliferate more at high ratio in co-cultured with sMSCs. CD4+ T cells from (a,d) 
Healthy (n = 5), (b,e) SLE (n = 5) and (c,f) LN (n = 5) were co-cultured with sMSCs at (a–c) 1:1 and (d–f) 1:100 
ratio (MSCs:T cells) and proliferation was measured at day 5, 7 and 10. To investigate if the proliferation was 
contact dependent, CD4+ T cells from a Healthy donors (n = 2) were co-cultured with sMSCs and nsMSCs, 
or cultured alone at (g) 1:1 and (h) 1:100 ratio (MSCs: CD4+ T cells) in a Transwell system. Proliferation was 
measured at day 5, 7 and 10. CD4+ T cells from (i,j) Healthy (n = 3) were co-cultured with sHUV and nsHUV 
at 1:1 (i) and 1:100 ratio (j) and proliferation was measured at day 5, 7 and 10. Data are shown as optical 
density mean ± SEM. Two-way ANOVA and with post-hoc analyses Dunnett’s (compare different days within 
a group toward day zero, marked with #) and Tukey’s (compare stimulated and non-stimulated setups toward 
CD4+ T cells cultured alone at a given time point, marked with * and compare stimulated setup toward non-
stimulated setup at a given time point, marked with+) multiple comparison tests. */#P < 0.05; **/##P < 0.01; 
***/###P < 0.001; ****/####P < 0.0001. (*/#co-cultured with sMSCs or sHUV, */#co-cultured with nsMSCs or 
nsHUV).
www.nature.com/scientificreports/
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MSCs33. Other studies have also shown that the dichotomous effect of MSCs was dependent on MSC:lymphocyte 
ratio where the homeostatic IL-2, IL-6 and IL-7 cytokines appeared to be involved32,34. Supporting this, we 
observed a stimulatory effect at low number of both nsMSCs and sMSCs on the proliferation of T cells isolated 
from the three groups compared to the effect of T cells alone. Indicating that even nsMSCs has the ability to 
stimulate the CD4+ T cells. For the Healthy and SLE group a reduced proliferation of CD4+ T cells in culture 
with nsMSCs were observed compared to sMSCs. This was not detected for the LN group and may indicate a 
different composition of lymphocyte subsets and activation levels of T cells in patients with LN, compared to SLE 
patients and healthy donors3,46–48. Surprisingly we were able to culture T cells alone for 10 days in absence of IL-2. 
There were no significant difference in the live cell population in cultures of T cell alone compared to T cells in 
co-culture with nsMSCs and sMSCs. Indicating a specific proliferation of unstimulated T cells when co-cultured 
with sMSCs. Najar et al. proposed that MSC-mediated inhibition was optimal at a 1:4 and 1:8 MSC:T cell ratio32, 
whereas others have reported inhibition at a 1:1 ratio34. Interestingly, nsMSCs increased the CD4+ T cells pro-
liferation from healthy donors largely in the transwell system, indicating a partial contact dependent inhibitory 
effect of nsMCSs on CD4+ T cells proliferation, which we did not observe in sMSCs. nsMSCs expressed IL-7, 
IL-1β, and CXCL12, which their role in inducing proliferative response in T cells have been discussed49–51.
On the other side, several studies have shown that the activation of MSCs with proinflammatory cytokines 
can induce MSCs to be more immunosuppressive vs, nonstimulated MSCs52–54. Han et al. demonstrated that 
IFNγ and TNFα stimulated MSCs had an immunosuppressive effect in vivo in a tumor inflammatory environ-
ment and thereby promoted tumor growth. In a study by Sivanathan et al., IL-17 stimulated MSCs were more 
immunosuppressive than IFNγ stimulated or unstimulated MSCs. IFNγ together with TNFα, IL-1α, or IL-1β 
induced the immunosuppressive function of MSCs by upregulating inducible nitric oxide synthase (iNOS) and 
many chemokines attracting immune cells52. Ren et al. showed that only the combination of all cytokines gave 
the highest immunosuppressive response of MSCs. In addition, the maximum inhibition was observed on acti-
vated T cells52. In our experiments, we focused on the CD4+ T cells and the effect of sMSCs and usMSCs on the 
proliferation and differentiation of these. Several studies and review paper have addresses the dual function of 
immunosuppressive vs immunestimulating potential of MSCs22,55. The MSCs may have different properties and 
functions depending on the inflammatory milieu and disease setting. In the developing TLS, the recruitment of 
Figure 7. CD4+ T cells from the Healthy group differentiate into Th2 and Th17 subsets in direct co-culture 
with sMSCs. After co-culturing at 1:1 ratio and 1:100 ratio with nsMSCs and sMSCs or cultured alone, CD4+ 
T cells from Healthy, SLE and LN groups were analyzed by FACS. The T cells co-cultured 1:100 with nsMSCs, 
sMSCs or cultured alone were analyzed for (a) Th1, (b) Th2, (c) Th17, (d) Th9, (e) Th1/17 and (f) Th22. Data are 
shown as % population mean ± SEM. One-way ANOVA with Post-hoc analysis Sidak’s multiple comparisons 
test (compare within groups, marked with *). *P < 0.05.
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naïve T cells by activated MSCs may be important for the expansion and activation of tissue specific effector T 
cells and need to be further investigated.
Our results suggest that an inflammatory environment could promote MSCs to secrete cytokines such as IL-1β 
and TNF-α, in addition to CCL19 to recruit T cells at the site of inflammation. It is known that IL-17 induces 
MSCs production of CXCL13 to recruit B cells, and that Th2-type cytokines and IL-23 induce naïve B cell prolif-
eration and differentiation into plasma cells at a site of TLS formation10,28,56,57. We also showed that MSCs express 
ICAM1, VCAM1, and HLA-DRA, and that the interaction with T cells resulted in activation of CD4+ T cells and 
differentiation into inflammatory T helper cells like Th2 and Th17. The dual impact of MSCs in suppressing and 
inducing Th1, Th2, and Th17 response has been extensively discussed58–62. It has been shown that CD4+ T cells 
in LN patients are stimulated and activated towards a Th1, Th2, and Th17 orientation2,47,63,64, and the involvement 
of IL-1β, IL-6, IL-21, IL-23, and HLA-DR play pivotal roles in Th2 and Th17 responses16,65–68. This could partially 
explain our results, which indicate that high expression levels of these cytokines in sMCSs co-cultured with T 
cells isolated from healthy donors at high ratio potentially promote both Th2 and Th17 response at the same time. 
These findings, to the best of our knowledge, have previously not been reported. However, T cells from SLE and 
LN patients did not significantly differentiate into the different Th subsets. There are several possibilities for this 
observation. First, if the patients were in an active state of the disease the response might have been stronger. 
Figure 8. Stimulated MSCs express higher levels of homeostatic cytokines and chemokines in co-culture with 
CD4+ T cells from the Healthy group. (a) MSCs (n = 7) were stimulated for 6 h with IL-1β and TNF-α (8 ng/
ml) and analyzed for the mRNA expression of CCL19, IL-1β, TNF-α, ICAM1, CXCL13, LTβ, CCR5, CCR7, 
IDO, HLA-DRA, IL-6, IL-21 and IL-23 at day 0 and day 10. Results are given as FC mean ± SEM compared 
to nsMSCs at day 0. (b) nsMSCs and sMSCs in co-culture with CD4+ T cells at 1:100 ratio from the Healthy 
group (n = 3). Results are given as FC mean ± SEM compared to nsMSCs at day 10. (c) nsMSCs and sMSCs in 
co-culture with CD4+ T cells at 1:100 ratio from the LN group (n = 3). Results are given as FC mean ± SEM 
compared to nsMSCs at day 10. (One-way ANOVA with Post-hoc analysis Dunnett’s multiple comparisons 
test (compared within a group toward nsMSCs at given time point, marked with *). *P < 0.05; **P < 0.01; 
***P < 0.001; ****P < 0.0001.
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Second, the already activated T cells from SLE and LN patients were not able to differentiate further. Third, the 
activated T cells in SLE and LN patients were not within the circulation but located in effected tissues, and thus 
could not be isolated from blood.
Rangel-Moreno et al. demonstrated that Th17, IL-17-producing CD4+ T cells, can induce TLS formation 
in the lung of mouse model lacking LTi cells57. They explained that IL-17 could induce CCL19 and CXCL13 
production in stromal cells, which lead to recruitment of B and T cells. In addition, IL-17 could also contribute 
to maintenance of the FDCs network57. Peters et al. showed that Th17 cells could promote TLS formation in the 
central nervous system in a mouse model of multiple sclerosis comprising T cells, plasma cells, and distinct B 
cell aggregation surrounded by reticulin as a lymphatic tissue supporting network69. The role of Th2 response/
subtype/cells in TLS development remains elusive. Stromal precursor cells could propagate to mature FDCs upon 
LTβR activation by α1β2 integrin on T cells70. Nayar et al. demonstrated that type 2 (Th2) cytokines, IL-4 and 
IL-13, could trigger the transition of residential stromal cells71 and adipose-derived stem cells72 to “lymphoid” 
stromal cells. Type 2 cytokine (IL-4) produced by Th2 cells could also induce expression of LTα1β2 on naive T 
cells required for future CD4+ T cells (LTi) and MSCs (LTo) interactions73. These facts are emphasizing the crit-
ical roles of Th2 and Th17 cells in promoting local inflammation and TLS development.
In the present study, we demonstrate that the expression of proinflammatory cytokines IL-1β and TNF-α, in 
addition to ICAM1, VCAM1, HLA-DR, and CCL19 were induced in sMSCs compared to non-stimulated cells. 
However, the expression of B cell homing cytokine CXCL13 and IL-23 could not be induced by single cytokine 
stimulation. Contrary, the sMSCs in co-cultured with T cells isolated from the healthy donors, expressed high 
levels of CXCL13, IDO, HLA-DR, IL-21, and IL-23, but not CCL19. Interestingly, this expression pattern was 
not observed in sMSCs co-cultured with T cells from SLE and LN patients. These patients were pre-treated with 
acetylsalicylic acid, hydroxychloroquine, methotrexate, and mycophenolate mofetil (MMF), which are known 
to affect the immune system and thereby effecting cytokine production, T cell activation and proliferation74,75. 
Hence, this could indirectly effect the response and capacity of the MSCs. However, our findings indicate that 
MSCs in an inflammatory environment may be important in both attracting T cells and B cells, in addition to 
contributing to the inflammatory response at an early phase. Our data suggest that MSCs after in vitro stimulation 
might acquire FRC-like phenotype expressing CCL19. However, after co-culturing with T cells they acquired an 
FDC-like phenotype expressing CXCL13 to attract B cell to the site of inflammation. This is in accordance with 
the findings of Peduto et al.38. They suggested that gp38+ “lymphoid” stromal cells could consist of different stro-
mal cell subsets or maturation stages based on genes and markers profile. They identified a CXCL13 expressing 
gp38+ stromal cells subset distinct from the CCL19 expressing subset38. It has been discussed that most of FDCs 
rise from migratory precursors with a mesenchymal origin76. Muñoz-Fernández et al. proved that FDCs originate 
from bone marrow stromal cell progenitors77. It has been shown that stimulation of FDC stromal precursor cells 
through LTβR and TNFR1 drives their differentiation to FDCs70,78.
The development of TLS within chronic inflamed tissues has been extensively reviewed79,80. Formation of 
TLS within target organs in autoimmune diseases like rheumatoid arthritis, Sjögren syndrome, and SLE, among 
others, indicate a tissue specific development of these structures79. TLS has been associated with the severity of 
autoimmune diseases and there are increasing evidence that tissue specific stromal cells play a role in the induc-
tion of TLS12.
As a new model for the formation of kidney-specific TLS and progression of LN in lupus-prone mice we pro-
pose that migratory or residential MSCs in the pelvic wall within the kidney of lupus-prone mice could potentially 
reprogram into LTo cells upon stimulation at an early stage of SLE progression. This might result in proinflamma-
tory cytokine production and overexpression of adhesion molecules that can lead to activation and recruitment of 
residential CD4+ T cells as LTi cell and consequently LTo/LTi cells crosstalk. The LTo/LTi cells interaction could 
promote CD4+ T proliferation and differentiation toward Th2 and Th17 subsets, which continue as a positive 
loop and aberrant accumulation of other immune cells and enlargement of networks of lymphatic and stromal 
cells. All prior events lead to the development of large TLS with GCs reaction and local autoantibody production, 
which may result in the progression of LN. The role of autoantibody production in TLS need further studies.
Methods
Animals. (NZBxNZW)F1 (B/W) were obtained from Jackson Laboratory (Bar Harbor, Maine, USA). 
Treatment and care of animals were conducted in accordance with guidelines of the Norwegian Ethical and 
Welfare Board for Animal Research, and the Norwegian Food Safety Authority (FOTS) approved the study.
Anti-dsDNA antibody enzyme-linked immunosorbent assay (ELISA) and measurement of pro-
teinuria. The level of anti-dsDNA antibody in lupus-prone mice serum was measured as described previ-
ously81. Blood samples were taken every week until positive ELISA test, and thereafter every second week until 
proteinuria was detected in urine. The protein in the urine was determined by urine dipstick (Bayer Diagnostics, 
Bridgend, United Kingdom): 0–1+ (<1 g/liter), was regarded as physiological proteinuria; 2+ (≥1 g/liter to 3 g/
liter) and 3+ (≥3 g/liter to 20 g/liter) and 4+ (≥20 g/liter). Proteinuria was defined as 4+.
Antibodies. CD4-VioGreen (130-106-655, Miltenyi Biotec), Anti-CCR10-PE (clone: REA326, 130-104-
822, Miltenyi Biotec), CD183 (CXCR3)-PE-Vio770 (clone: REA326, 130-104-822, Miltenyi Biotec), CD194 
(CCR4)-APC (clone: REA279, 130-103-813, Miltenyi Biotec), CD196 (CCR6)- PE-Vivo-615 (clone: REA190, 
130-107-142, Miltenyi Biotec), Propidium iodide (130-093-233, Miltenyi Biotec), NESTIN rabbit-anti-mouse 
(ab7659, Abcam), SCA1 rat-anti-mouse (ab25195, Abcam), PDGFRα goat-anti-mouse (AF1062, R&D Systems), 
Alexa Flour 405 donkey-anti-Rabbit (ab175651, Abcam), Alexa Flour 488 donkey-anti-goat (A-11055, Thermo 
Fisher Scientific), Alexa Flour 594 donkey-anti-rat (A-21209, Thermo Fisher Scientific), PerCP-CyTM 5.5 CD45.2 
conjugated mouse-anti-mouse (552950, BD Biosciences), ICAM1 rabbit-anti-human (ab53013, Abcam), VCAM1 
www.nature.com/scientificreports/
1 2ScIeNTIFIc REPORTS |  (2018) 8:7861  | DOI:10.1038/s41598-018-26265-z
rabbit-anti-human (ab134047, Abcam), IL-1β rabbit-anti-human (ab2105, Abcam), TNF-α rabbit-anti-human 
(ab9635, Abcam), actin rabbit-anti-human (A2066, Sigma-Aldrich), rabbit anti goat (81–1620, Invitrogen), goat 
anti rabbit (65–6120,Invitrogen), CD3 rabbit-anti mouse (AD452, Dako), and B220 rat-anti-mouse (MAB1217, 
R&D Systems).
Immunofluorescent staining and Fluorescence Confocal Microscopy. Detection of NESTIN, SCA1, 
PDGFRα, and CD45 were performed on kidney cryosections (4 µm) from (NZBxNZW)F1 mice. Dried sec-
tions were fixed in 4% paraformaldehyde for 5 minutes and washed twice in 1xPBS for 5 minutes. Sections were 
blocked with 10% donkey serum in PBS for 30 minutes, and incubated for 30 minutes with primary antibodies 
(NESTIN 10 μg/ml, Sca1 10 μg/ml, and PDGFRα 2 μg/ml). Washed sections were incubated with secondary anti-
bodies Alexa Flour 405, Alexa Flour 488, Alexa Flour 594, Alexa Flour 647 (all three 2 μg/ml) and PerCP-CyTM 
5.5 mouse-anti-mouse CD45.2 conjugated (4 μg/ml). Slides were washed, dried, and mounted using Mowiol 
(Sigma-Aldrich). The sections were examined by LSM780 AxioObserver (Carl Zeiss, Oberkochen, Germany), 
and the intensity were measured by drawing a line in the area of interest. The intensity of different signals (num-
ber based) for the whole length of the line were determined. For each image, two lines were drawn, one in the 
CD45+ area and one in PDGFRα+ area.
Immunohistochemistry. Detection of CD3 positive T cells (Dako, 3 μg/ml) and B220 positive B cells 
(R&D systems, 0.83 μg/ml) in 4 µm paraffin embedded kidney sections were performed as described previously36. 
Envision+ system-HRP/DAB anti rabbit detection kit (K4011, Dako) and Polink-2 Plus HRP Anti-Rat DAB 
detection Kit (D46-15, Golden Bridge International) were used to detect CD3 and B220 respectively.
RNA isolation and qPCR of murine kidneys. Total RNA from kidney tissue (10 mg) and dissected 
TLS and kidney tissue preserved in RNAlater (Ambion Inc., Texas) was isolated with the EZ1 RNA Tissue 
Mini Kit (Qiagen, Nordic, Norway) according to the manufacturers’ protocol. The isolated RNA was then 
reverse-transcribed with random primers using High-Capacity cDNA Reverse Transcription kit (4368814, 
ThermoFisher Scentific). Real-time PCR was performed on an ABI Prism 7900HT Sequence Detection System 
(Applied Biosystems) with the following TaqMan gene expression assays: TBP, LTB, LTBR, CCL19, CXCL13, 
VCAM1 and ICAM1 (Supplementary Table S4). TaqMan Fast Universal PCR master mix (2X) and gene expres-
sion assays were all obtained from Applied Biosystems (Foster City, USA). Gene expression was normalized 
against the reference gene TBP for each mouse. Average of young mice (4 w.o, n = 3) served as reference for total 
kidney and dissected TLS and kidney tissue and changes in gene expression were calculated with the ΔΔCT 
method shown as fold change (FC). Young mice age 4–18 wo (n = 35), Ab+ mice age 18–28 wo (n = 28), and 
proteinuric mice 23–39 wo (n = 27).
Healthy and SLE subjects. Peripheral blood samples were obtained from patients diagnosed with SLE 
and LN according to the 1997 American College of Rheumatology Revised Criteria for classification of SLE82,83. 
Peripheral blood samples from random healthy donors were obtained from the blood bank at University Hospital 
of North Norway (UNN, Tromsø Norway).
MSCs, HMLE and HUV-EC-C stimulations. Single cytokine stimulations. Bone marrow-derived MSCs 
(Normal, Human; ATCC® PCS-500-012) (p.9) were plated in a flat-bottomed 6 well plate (Corning Inc, US) at 
2.0 × 105 cells/ml for 24 hours, following serum reduction for 18 hours in complete medium (ATCC PCS-500-
030)(Supplementary Table S5) containing 3% fetal bovine serum (FBS). Cells were stimulated with the following 
cytokines IL-1β (201-LB, R&D Systems), TNF-α (210-TA, R&D systems), IFN-α (11100-1, R&D systems), INF-γ 
(285-IF, R&D systems), IL-6 (206-IL, R&D systems), and IL-10 (217-IL, R&D systems) at 2, 4, 8, 16, 20, 25, and 
35 ng/ml for 24 hours in complete medium containing 0.1% FBS.
Combined cytokine stimulations. MSCs (p.9) were plated in 12 well plates at 1.0 × 105 cells/ml for 24 hours, 
and starved in complete medium containing 3% FBS for 18 hours. Based on the results from the single cytokine 
stimulation, cells were stimulated with IL-1β (8 ng/ml) and TNF-α (8 ng/ml) in complete medium containing 
0.1% FBS for 1–72 hours. The same experiment was performed with the HUV-EC-C cells (Normal, Human; 
ATCC® CRL-1730TM) and HMLE cells (Robert Weinberg, Whitehead Institute for Biomedical Research and 
Department of Biology, Massachusetts Institute of Technology). HMLE cells were not starved prior to stimulation 
(Supplementary Table S3).
T Cell Isolation. LymphoprepTM (STEMCELL Technologies) was used to isolate peripheral blood mononu-
clear cells (PBMCs) from buffy coat or heparinized blood obtained from the blood bank (UNN, Tromsø Norway), 
according to the manufacturer’s instructions. Enriched CD4+ T cells were obtained by negative selection from 
lymphoprep-PBMCs pellets using the magnetic CD4+ T cell human isolation kit (130-096-533 Miltenyi Biotec) 
and LS Column (Miltenyi Biotec).
T cell co-cultures. Direct contact. Bone marrow-derived MSCs were cultured in complete medium at 37 °C 
in 5% CO2. Cells (p.9) were plated in a flat-bottomed 24 well (Corning Inc, US) for proliferation assay (2.0 × 103) 
and flow cytometry analysis (5.0 × 103) for 24 hours. Cells were starved for 18 hours in complete medium con-
taining 3% FBS, stimulated with 8 ng/ml IL-1β and TNF-α in complete medium containing 0.1% FBS for 6 hours, 
washed twice with 1xPBS. CD4+ T cells were subsequently added to the wells at 1:1 and 1:100 ratios (MSCs: 
CD4+ T cells). The same experiment was performed with the HUV-EC-C cell line.
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Transwell system. MSCs and HUV-EC-C cells were plated in a 24 well cell culture insert companion plate 
Falcon® (734-0067, Corning) at 2.0 × 103 cell/ml. CD4+ T cells were subsequently added to the PET membrane 
inserts Falcon® with 0.4 μm pore size (734-0036, Corning) at 1:1 and 1:100 ratios for use in the proliferation assay. 
MSCs and HUV-EC-C cells were plated in a 24 mm Transwell® plate at 8.0 × 103 cell/ml and CD4+ T cells were 
added to polyester membrane insert with 3 µm pore size (CORN3452, Corning) at 1:1 and 1:100 ratios for use in 
flow cytometry analysis.
Proliferation Assay. At day 0, 5, 7, and 10, the proliferation of CD4+ T cells co-culture with sMSCs, nsMSCs 
(direct contact and Transwell system), sHUV-EC-C cells, nsHUV-EC-C cells (direct contact) and CD4+ T cells 
cultured alone were measured. Cell suspensions of CD4+ T cells were transferred to new wells and added 50 μL 
of AlamarBlue® (DAL1100, ThermoFisher Scientific) to a final concentration of 10% (V/V). After 3 hours of incu-
bation at 37 °C in 5% CO2, fluorescence of reduced AlamarBlue® in the supernatant was measured (λex = 540 nm, 
λem = 590 nm) with a CLARIOstar® microplate reader (BMG LABTECHq).
RNA isolation and qPCR of cells. Cells were harvested and total RNA was isolated using TRIzol 
(ThermoFisher Scientific), and High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) was used 
to synthesize cDNA. Real-time qPCR was performed with the LightCycler® Analysing machine (Roche Holding 
AG) using TaqMan gene expression assays (ThermoFisher Scientific) (Supplementary Table S4) and TaqMan® 
Fast Universal Master Mix (Applied Biosystems). Total cDNA input was normalized to the reference gene meas-
ured in parallel qPCR reactions. Real-time qPCR data is presented as relative expression using ΔΔCT method 
in which relative expression = 2−ΔΔCT. Each sample was run in duplicates and threshold cycle (Ct) values were 
averaged from each reaction. TBP was used as reference gene. Where no Ct values were detected for the controls 
the Ct value were set to 37 for statistical calculations.
FACS. Surface marker staining was performed on enriched CD4+ T cells from PBMCs at day zero, CD4+ T 
cells co-culture with sMSCs, nsMSCs (direct contact and Transwell system), sHUV-EC-C cells, nsHUV-EC-C 
cells (direct contact and Transwell system) and CD4+ T cells cultured alone at day ten. Cells were pelleted down 
and resuspended in 100 μl staining buffer (containing phosphate-buffered saline (PBS), pH 7.2, 0.5% bovine 
serum albumin (BSA), and 2 mM EDTA). Antibodies CD4-VioGreen (0.034 μg/ml), CCR10-PE (0.034 μg/ml), 
CD183 (CXCR3)-PE-Vio770 (0.02 μg/ml), CD194 (CCR4)-APC (0.068 μg/ml), CD196 (CCR6)-PE-Vivo-615 
(0.013 μg/ml) were added and incubated for 10 min at 4 °C in the dark. Cells were washed with 1 ml staining 
buffer, pelleted and resuspended in 100 μL MACSQuant running buffer (Miltenyi Biotec). 5 μL of Propidium 
iodide (Miltenyi Biotec) was added shortly before running the samples on FACSARIA III (BD Biosciences). Data 
were analyzed with FlowJo software (v10, FlowJo LLC). To compensate optimally for fluorescence spillover from 
fluorochrome-conjugated antibodies, the MACS Comp Bead Kit, anti-human (130-104-187, Miltenyi Biotec) and 
anti-mouse (130-097-900, Miltenyi Biotec) Igκ(Miltenyi Biotec) were used.
Immunoblotting. Cells harvested with RIPA buffer containing phosphatase and protease inhibitors (Thermo 
Fisher Scientific) were sonicated (Bioruptor 300, Diagenode) for 5 minutes and protein concentration was meas-
ured using Direct Detect® Spectrometer (Merck Millipore). Boiled samples (20 μg protein, 4 μl LDS, and 1.4 μl 
reducing agent) were separated on Bis-Tris protein gel (Thermo Fisher Scientific) and transferred to nitrocellu-
lose membrane (LI-COR Biosciences). The membrane was blocked with 5% nonfat skim milk (Bio-Rad) for one 
hour and incubated with primary antibodies (ICAM1 0.03 μg/ml, VCAM1 0.22 μg/ml, IL-1β 2 μg/ml and, TNF-α 
2 μg/ml) overnight at 4 °C. Proteins were detected using appropriate HRP-conjugated antibodies (rabbit anti goat 
0.75 μg/ml, goat anti rabbit 0.67 μg/ml) and SuperSignal West Pico chemiluminescent substrate (Thermo Fisher 
Scientific) to obtain images with ImageQuant LAS 4000 Imager (GE Healthcare Life Sciences).
Statistics. We performed Two-way ANOVA with Post-hoc analysis (Sidak’s and Dunnett’s multiple compar-
isons test) for cell culture qPCR data, Two-way ANOVA with Post-hoc analyses (Dunnett’s and Tukey’s multiple 
comparisons tests) for proliferation data, One-way ANOVA with Post-hoc analysis (Sidak’s multiple comparisons 
test) for Flow cytometry data, and Kruskal-Wallis test with Dunn’s Multiple Comparison Test for kidney tissue 
qPCR data. A p-value of ≤0.05 was considered statistically significant and data are presented as mean ± SEM.
Study approval. For animal studies, the Animal Welfare Board, at the UiT–The Arctic University of Norway 
and the Norwegian Food Safety Authority (NFSA, Mattilsynet) approved all procedures. Patients and healthy 
individuals were recruited through the Department of Rheumatology, University Hospital of North Norway and 
the Regional Committees for Medical and Health Research Ethics (REK) approved the project. Informed consent 
was obtained from all patients and healthy individuals before sample collection. The REK approved all experi-
mental protocols involving human participants and samples (REK 2015/1315). We confirm that all experiments 
were performed in accordance with relevant guidelines and regulations.
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Supplementary Figure S1: Nestin, Sca1, PDGFRα, and CD45 Signal intensity. The signal 
intensity graphs represent the intensity of four different signals Nestin, Sca1, PDGFRα, and 
CD45. Each group (A) Ab-, (B) Ab+, and (C) proteinuric contain two graphs, which indicate 







Supplementary Figure S2: Stimulated HMLE and HUV-EC-C cells express proinflammatory 
cytokines and adhesion proteins. HUV (n=3) cells were stimulated with IL-1β and TNF-α (8 
 
 
ng/ml) and mRNA expression of (A) IL-1β, (B) TNF-α, (C) VCAM1, and (D) ICAM1 were 
measured after 1-72h. HMLE (n=3) cells were stimulated with IL-1β and TNF-α (8 ng/ml) and 
mRNA expression of (E) IL-1β, (F) ICAM1, and (G) TNF-α were measured after 1-72h. Results 
are shown as FC mean ± SEM compared to Ctr at the same time points. (H) HUV (n=3) were 
stimulated for 6h with IL-1β and TNF-α (8 ng/ml), and analyzed for the mRNA expression of 
CCL19, IL-1β, TNF-α, ICAM1, CXCL13, LTβ, CCR5, CCR7, IDO, HLA-DRA, IL-6, IL-21 and IL-23 at 
day 0 and day 10. Results are given as FC mean ± SEM compared to nsHUV at day 0. (I) nsHUV 
and sHUV in co-culture with CD4+ T cells at 1:100 ratio from Healthy donors (n=3). Results are 
given as FC mean ± SEM compared to nsHUV at day 10. (A-G) Two-way ANOVA with Post-hoc 
analysis Sidak’s (*) and Dunnett’s (compare within a group toward zero hour time point, 
marked with #) multiple comparisons tests. */#P < 0.05; **/##P < 0.01; ***/###P < 0.001; 
****/####P < 0.0001. 
(H-I) One-way ANOVA with Post-hoc analysis Dunnett’s multiple comparisons test (compared 
within a group toward nsMSCs or nsHUV at given time point, marked with *). *P < 0.05; **P < 







Supplementary Figure S3: Higher Th1 and Th9 subsets were observed in T cells from Healthy 
group compared to SLE and LN. 
(A) Illustrated gating strategy used to define the different Th cells subsets. Purified CD4+ T 
cells from the Healthy donors (n=5), SLE patients (n=5), and LN patients (n=5) were analyzed 
by FACS. After gating for singlets and subsequently live cells; cells were analyzed for CD4. The 
CD4+ cells were used further to analyze Th cells subsets based on expression of surface 
markers: (B) CXCR3+CCR10-CCR6- for Th1 (C) CCR4+CXCR3-CCR10-CCR6- for Th2, (D) 
 
 
CCR4+CXCR3-CCR10-CCR6+ for Th17, (E) CCR4-CCR6+ for Th9, (F) CCR4-CXCR3+CCR6+ for 
Th1/17cells, and (G) CCR4+CCR6+CCR10+ for Th22. After co-culturing at 1:1 ratio and 1:100 
ratio with nsMSCs and sMSCs or cultured alone, CD4+ T cells from Healthy, SLE and LN groups 
were analyzed by FACS. The % of live T cell population from (H) Healthy (n=5), (J) SLE (n=5), 
and (I) LN (n=5) group were measured at day zero and after 10 days in co-culture. Data are 
given as % cell population mean ± SEM. One-way ANOVA with Post-hoc analysis Sidak’s 
multiple comparisons test (compare within groups, marked with *). *P < 0.05; **P < 0.01; 








Supplementary Figure S4: CD4+ T cells from the Healthy group do not differentiate into Th2 
and Th17 subsets in indirect co-culture with sMSCs. 
To analyze if the differentiation was contact dependent CD4+ T cells from the Healthy (n=3) 
or Lupus (n=3, SLE n=1, LN n=2) groups were co-cultured at 1:100 ratio (MSCs:CD4+ T cells) 
with nsMSCs, sMSCs or cultures alone in a Transwell system. The T cells were analyzed for (A) 
Th1, (B) Th2, (C) Th17, (D) Th9, (E) Th22, and (F) Th1/17 subtypes at day zero and at day 10. 
Data are shown as % population mean ± SEM. One-way ANOVA with Post-hoc analysis Sidak’s 






Supplementary Table S1: Gene expression in MSCs after single stimulation with TNF-α and 
IL-1β. 
 









Supplementary Table S2: Gene expression in MSCs after single stimulation with IL-10, IL-6, 
IFN- γ, and IFN-α. 
 















Patient Sex. Age (y) Disease 
duration 














1 M 53 6 mth SLE Hem(Ly), Se (Pl), 
Diskoid ANA, Im 
RP, Lymph anti-dsDNA, LAC, low C3 - 4 MTX, PRED, 
HCQ 
2 M 58 5 y SLE Rash, Ph, Hem-Le, Ar, 
ANA, 
Sicca, pre-OP SSA, SSB - 3 HCQ, Ale, CF 
3 F 36 17 y SLE Er, Rash, Hem-Le, Ar, 
ANA, 
RP, SICCA dsDNA, anti-sm, Comp, 
ACA-IgM, ACA-IgG, ACA-
B2-IgA 
- 7 ASA, AZA, 
HCQ, PRED, 
CF 
4 F 20 12 y SLE Diskoid, rash, Ou, Ar, 
ANA, Im, Hem (Ly), 
CNS? 
Alopecia Anti-SSA - 0 HCQ, AZA, 
LIT 




Anti-SSA - 0 AZA, PRED 
6 F 33 6 y LN Rash, Ou, Ar, N, ANA, 
Im 
RP RNP, anti-dsDNA AB Class 2 (6 y) 
Class 4 (3 y) 
3 MMF, PRED, 
ENA, HCQ, 
CF 
7 F 38 1 y LN N, ANA, Hem(Ly), Im, CAC, IRI PCOS, APS, 
latent TB, SSS 
ACA-B2-IgA, ACA-IgA, 
ACA-IgM, anti-RNP, anti-
SSA, anti-SSB, anti-Sm 
Class 3A (1 y) 
Class 5 (1 y) 
0 MP, MMF, 
HCQ, ASA 
8 F 73 1 y LN Ph, Rash, Hem(An), N, 
Im, Ar 
TC (-89), PT, 
HBP,BCC-RE, Hip-OA, 
Epilepsy (-02) 




9 F 64 28 y LN N, Im APS anti-DNA, , anti-smD, low 
C3, 
Class 2 (16 y) 4 HCQ, PRED 
10 F 61 31 y LN Ar, Discoid, N, Hem(Ly) APS dsDNA, SSA, low C3/C4 
(normal at time of test) 






Supplementary Table S4: Cell lines, media and growth kit: 
Cell line  Basal media  Supplemented with 
MSC (ATCC® PCS-500-
012) * 
Mesenchymal stem cell basal 
medium (PCS-500-030, ATCC) 
Mesenchymal stem cell growth kit – for bone 
marrow derived MSCs (PCS-500-041, ATCC). 
Containing L-alanyl-L-Glutamine, FBS, rh GF-1, 





1:1 mixture of MEGM™ Mammary 
Epithelial Cell Growth Medium 
(Lonza) and DMEM/F12 
(11320033, Thermo Fisher) 
 
10ng/mL EGF 0.5 μg/mL hydrocortisone 




F-12K Kaighn´s Modification of 
Ham´s F12 media (30-2004, ATTC) 
0,1mg/mL of sodium heparin (H3393-199KU, 
Sigma Aldich), 0,03% endothelial cell growth 
supplement (ECGS, E2759, Sigma Aldrich), 1% 
penicillin-streptomycin (P0781-100mL, Sigma-
Aldrich) and 10% Fetal bovine serum (FBS, 
7524, Sigma-Aldrich) 
* Differentiation test to adipocytes, chondrocytes, and osteocytes passed positive. MSCs 
specific staining test: positive for CD29, CD44, CD73, CD90, CD105, CD166 and negative for 
CD14, CD19, CD34, and CD45. Doubling capacity: up to 17 doublings, cells morphology was 

































Supplementary Table S5: TaqMan gene expression assays 
Gene Cat.nr Gene Cat.nr Gene Cat.nr 
Human           
CCL19 HS00171149 TBP HS00427621 HLA-DRA Hs00219575 
CCL21 HS00989654 CXCL12 HS03676656 IL-2 Hs00174114 
CXCL13 HS00757930 IL-7 HS00174202 IL-12 Hs01073447 
ICAM1 HS00164932 IL-4 HS00174122 IL-21 Hs00222327 
IL-1  HS00174097 RANKL HS00243522 IL-23 Hs00372324 
LT R HS00158922 CCR5 HS99999149     
LTβ HS00242739 CCR7 HS01013469     
TNF-  HS00174128 PDPN HS00366766     
VCAM1 HS01003372 IDO1 Hs00984148     
Murine            
CCL19 Mm00839967_g1 LT R Mm00440235_m1 ICAM1 Mm00516023_m1 
CXCL13 Mn0444533_m1 LTβ Mm00434774_g1 VCAM1 Mm01320970_m1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
